1 Sept 2026
Mutant isocitrate dehydrogenase in cancer: Structural biology, small-molecule inhibitors, and future drug discovery strategiesPublisher siteDrug Discovery Today, Colorectal Cancer Treatments and Studies
Active, last published 2026
In synthesis and biological activity
Haytham O.
Tawfik
Scholar“Research focused on Synthesis and biological activity and adjacent fields.”
Tanta University
Egypt
Claim Your ProfileEgypt22
H-index
1.1k
Citations
Haytham has not officially claimed their profile. If you are Haytham, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
aytham O. Tawfik is a researcher working on Synthesis and biological activity. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Haytham's work has been cited 1,140 times across 5 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Synthesis and biological activity×28Enzyme function and inhibition×16Synthesis and Catalytic Reactions×12Click Chemistry and Applications×11Cancer therapeutics and mechanisms×10
04 · Where I am
Affiliations
Affiliation on published researchTanta University, EgyptDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
54 works1 Aug 2026Open access
Targeting CDK‐2 With Novel Indole‐Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico StudiesPublisher siteDrug Development Research, Cancer-related Molecular Pathways
23 Jul 2026Open access
In silico pipeline for GSK 3β inhibitor discovery in Alzheimer’s disease using pharmacophore screening, docking, ADME filtering, and MD validationPublisher siteScientific Reports, Computational Drug Discovery Methods
21 Jun 2026
Identification of Sulfonamide‐Based Thiazolidine‐2,4‐Dione Derivatives as VEGFR‐2 and Tumor‐Associated hCA IX Inhibitors With Hypoxia‐Targeted Anti‐Colorectal Cancer ActivityPublisher siteDrug Development Research, Enzyme function and inhibition
26 Mar 2026
Isatin-triazole/imidazole hybrids as dual CDK2/VEGFR2 inhibitors with potent anti-cancer activity: design, synthesis, and biological evaluationsPublisher siteBioorganic Chemistry, Cancer-related Molecular Pathways
1 Mar 2026Open access
Synthesis and Biological Evaluation of Imidazopyridine-Isatin Hybrids as Inhibitors of Leishmania major GrowthPublisher siteDrug Design Development and Therapy, Research on Leishmaniasis Studies
1 Jan 2026Open access
Synthesis of new <i>trans</i> -ferulic acid derivatives as potential anticancer agents and VEGFR-2 inhibitorsPublisher siteRSC Medicinal Chemistry, Biological Activity of Diterpenoids and Biflavonoids
18 Dec 2025Open access
Discovery of enaminone-linked benzofuran derivatives as dual VEGFR-2/hCA IX inhibitors exhibiting hypoxia-mediated chemosensitizationPublisher siteRSC Medicinal Chemistry
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Haytham?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you